Stock Analysis
Verona Pharma plc (VRNA) Stock Analysis
Verona Pharma plc (VRNA) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Verona Pharma plc (VRNA) currently has an AIQ Score of 43/100, indicating a neutral setup. Risk is the strongest factor at 54/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
VRNA at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | — |
| AIQ Score | 43/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | — |
| Market Cap | $72.68B |
| P/E Ratio | -102.8 |
| Forward P/E | — |
| EPS | $0.10 |
| Revenue TTM | $75.14M |
| Dividend Yield | 0.00% |
| Beta | 0.05 |
| Volume | — |
| 52-week range | — |
| RSI 14 | — |
| 50-Day SMA | — |
| 200-Day SMA | — |
| Analyst Price Target | $107.00 |
| Next Earnings | — |
VRNA
OverviewVRNA Stock Analysis Summary
Verona Pharma plc (VRNA) currently has an AIQ Score of 43/100, indicating a neutral setup. Risk resilience is the strongest factor at 54/100. Value is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, VRNA has AIQ Score of 43/100 with Risk resilience base of 54/100 and fading Value at 34/100. Wait for component alignment before adding exposure.
Risk resilience (54/100) leads while Value (34/100) lags. This cross-factor spread creates entry timing uncertainty.
Healthcare · — stock move · VRNA classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is VRNA Bullish or Bearish Right Now?
VRNA currently has a neutral overall setup. Risk Resilience is the strongest factor at 54/100, while Value is weakest at 34/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - No strong bullish evidence is available in the current snapshot.
- - Value is the current constraint at 34/100.
Current Consensus
VRNA's Technical Analysis Consensus is currently —, with 0 buy, 0 neutral, and 0 sell votes. VRNA's beta is 0.05, indicating lower market sensitivity than the broad market.
What Changed in VRNA?
Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.
What Would Change the VRNA Outlook?
The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
VRNA Decision Framework
Public evidence layers, setup checks, and risk context for Verona Pharma plc.
Verona Pharma plc (VRNA) Stock Analysis
Verona Pharma plc has an AIQ Score of 43/100 in a Neutral regime. Risk is strongest at 54/100. Beta is 0.05, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | VRNA is in a Neutral AIQ regime with score 43/100. |
| Signal Conflict | The primary conflict is that risk leads at 54/100 while value lags at 34/100. |
| Factor Evidence | Value 34/100 · Quality 47/100 · Risk 54/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 54/100.
Momentum is —.
VRNA is in a Neutral regime at 43/100.
Risk factor is 54/100 with beta 0.05 and annual volatility 41.05%.
Current conflict: risk leads at 54/100 while value lags at 34/100.
VRNA Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
VRNA Fundamentals
VRNA valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
VRNA Technical Analysis
VRNA technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
VRNA Stock Catalysts
Track VRNA earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
VRNA Dividend Analysis
VRNA dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
VRNA Financial Data
VRNA revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
VRNA Risk Analysis
VRNA volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
VRNA Stock News
VRNA stock news, market tone, recent headlines, and catalyst context.
VRNA vs Gene Editing / Genomics / Biotech Peers
Current peer cohort: VRNA · WVE · XNCR · ACAD · ALNY. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| VRNA Current stock | 43/100 | 34/100 | — | 54/100 | 1.41 | 41.05% | Current |
| WVE Wave Life Sciences | 40/100 | 34/100 | 25/100 | 40/100 | 0.26 | 168.13% | VRNA vs WVE |
| XNCR Xencor | 45/100 | 34/100 | 47/100 | 55/100 | 1.88 | 67.18% | VRNA vs XNCR |
| ACAD Acadia Pharmaceuticals | 67/100 | 57/100 | 47/100 | 71/100 | 0.5 | 37.75% | VRNA vs ACAD |
| ALNY Alnylam Pharmaceuticals | 54/100 | 26/100 | 57/100 | 42/100 | -1.19 | 46.84% | VRNA vs ALNY |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts7 recent quarterly periods are available for review.
Checked Sep 11, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2025.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching VRNA
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for VRNA
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
VRNA Stock FAQ
What is VRNA stock price today?
Verona Pharma plc's current stock price is shown near the top of this overview when the latest quote is available. Use the quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is VRNA bullish or bearish right now?
VRNA's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is VRNA's market cap?
VRNA's market cap is $72.68B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is VRNA's current P/E ratio?
VRNA's current P/E ratio is -102.8 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is VRNA's RSI?
VRNA's RSI appears in the technical analysis view when market-close technical data is available. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is VRNA above its 50-day and 200-day moving averages?
VRNA's price versus the 50-day and 200-day moving averages helps describe trend confirmation. The overview and technicals page show this context when those moving-average fields are available.
When is VRNA's next earnings date?
VRNA's next earnings date is a key event to check before making a decision. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does VRNA pay a dividend?
VRNA's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.